Ritodrine

Summary

Ritodrine (CHEMBL83063) is an approved small molecule (ATC G02CA01).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: G02CA01
• Clinical trials: 3
• Chemistry: 287.35 Da · C17H21NO3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL83063
Name	Ritodrine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	31729
ChEBI	CHEBI:91775
ATC	G02CA01
Molecular formula	C17H21NO3
Molecular weight	287.35
InChIKey	IOVGROKTTNBUGK-UHFFFAOYSA-N

SMILES: CC(C(C1=CC=C(C=C1)O)O)NCCC2=CC=C(C=C2)O

IUPAC name: 4-[2-[[1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol

ChEBI definition: A secondary amino compound that is 4-(2-amino-1-hydroxypropyl)phenol in which one of the hydrogens attached to the nitrogen is replaced by a 2-(4-hydroxyphenyl)ethyl group.

Also known as: DU-21220, Ritodrina, Ritodrine, SID56463517, RITODRINE, SID174007152, ritodrine, RITODRINE HYDROCHLORIDE

Parent form; salt/anhydrous children: CHEMBL1367605

Patent coverage: 22 distinct patent families (38 SureChEMBL compound mentions), from 2 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 11 (assay-derived). Sample: Beta-2 adrenergic receptor, Beta-1 adrenergic receptor, Sodium-dependent noradrenaline transporter, Sodium-dependent serotonin transporter, Alpha-1A adrenergic receptor, Mu-type opioid receptor, Kappa-type opioid receptor, Sodium-dependent dopamine transporter, Galanin receptor type 3, Beta-2 adrenergic receptor.

Bioactivity

ChEMBL activities: 10 potent at pChembl ≥ 5 of 18 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P10608	7.62	IC50	23.99	nM	CHEMBL_ACT_1145133
P26255	6.72	EC50	190.6	nM	CHEMBL_ACT_1145134
GALR3	6.03	IC50	932	nM	CHEMBL_ACT_12851555
ADRA1A	5.81	AC50	1537	nM	CHEMBL_ACT_25138198
ADRA1A	5.7	AC50	2000	nM	CHEMBL_ACT_25218028
ADRB2	5.38	AC50	4140	nM	CHEMBL_ACT_25123258
ADRB2	5.33	AC50	4711	nM	CHEMBL_ACT_25122823
OPRM1	5.09	AC50	8100	nM	CHEMBL_ACT_25146891
OPRM1	5.04	AC50	9200	nM	CHEMBL_ACT_25157737
ADRA1A	5	AC50	10000	nM	CHEMBL_ACT_25137895

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE4	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03040752	PHASE4	COMPLETED	Comparative Study Between Nifedipine and Ritodrine as Maintenance Tocolytic Therapy in Preterm Labor
NCT03298191	PHASE4	UNKNOWN	Tocolysis in Prevention of Preterm Labor
NCT00679705	PHASE1	COMPLETED	Influence of Tocolytical Medications on Hemodynamics (Central and Peripheral) and Vascular Function in a Pilot Study to Determine the Design of the Final Study and the Final Study Itself

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).